The Efficacy, Mechanism & Safety of Sodium Glucose Co-Transporter-2 Inhibitor & Glucagon-Like Peptide 1 Receptor Agonist Combination Therapy in Kidney Transplant Recipients

ConditionKidney Transplant Recipients

Trial statusRecruiting

Trial phasePhase 2

Trial typeInterventional

Biological sexAll

Age18+

SponsorUniversity Health Network, Toronto

About this trial

The study aims to determine the short-term efficacy, mechanisms and safety of 12 weeks of dapagliflozin and semaglutide combination therapy in 20 KTR, with and without T2D.

Eligibility criteria

Qualifiers

Signed and dated written informed consent.

Patients aged ≥18 years with KTR

>3 months post kidney transplantation

Estimated glomerular filtration rate [eGFR] ≥20 ml/min/1.73m2

Disqualifiers

Type 1 diabetes.

History of multi-organ transplant

Acute coronary syndrome, transient ischemic attack or stroke within 30 days prior to screening

Impending need for kidney biopsy or rapid decline in eGFR within 30 days prior to screening

Trial design

Treatments tested in this trial

Dapagliflozin 10 MG
Semaglutide, 1.0 mg/mL

Treatment groups

20 Participants

are divided into 2 treatment groups

Sponsors and collaborators

University Health Network, Toronto

Lead sponsor

Source ClinicalTrials.gov